

## Healionics 2022 Q4 Update

In Q4 of 2022, we launched a human study of *STARgraft-3V* and continued development of our customized replacement ePTFE core for *STARgraft*.

### Financial Snapshot

12/31/22 Cash Balance: \$3,275k

Income in Q4:

Interest income + iSTAR royalty payment: \$25k

Operating Expenses in Q4: \$601k

### *STARgraft* Update

Our *STARgraft* vascular graft (synthetic blood vessel) is intended to provide a safer and more reliable means to access the bloodstream for dialysis in patients with kidney failure.

We completed preclinical testing and began a human study of *STARgraft-3V* in Paraguay, with the first five patients implanted in December. As the patients begin using the grafts to enable dialysis therapy, we are monitoring device performance and reliability with frequent follow-up exams.

We are also continuing to collaborate with Merit Medical to develop a customized replacement ePTFE core for *STARgraft* (as discussed in our Q3 update).

### iSTAR Medical

Our spinout company iSTAR issued a [year-end update](#) highlighting their continued commercial roll-out across Europe during 2022, with first implants of their *STAR*-based MINiject glaucoma device taking place in UK, Switzerland, Sweden and Norway, and significant sales expansion throughout Germany. They are also continuing to enroll patients in their U.S. clinical trial.

### Team Update

In November, we welcomed Biomaterials Manufacturing Engineer Molly Daigle to our team.

Best regards,  
Mike

Mike Connolly  
CEO  
[Healionics Corporation](#)